TY  - JOUR
AU  - Heinrich, Daniel
AU  - Bektic, Jasmin
AU  - Bergman, Andries M
AU  - Caffo, Orazio
AU  - Cathomas, Richard
AU  - Chi, Kim N
AU  - Daugaard, Gedske
AU  - Keizman, Daniel
AU  - Kindblom, Jon
AU  - Kramer, Gero
AU  - Olmos, David
AU  - Omlin, Aurelius
AU  - Sridhar, Srikala S
AU  - Tucci, Marcello
AU  - van Oort, Inge
AU  - Nilsson, Sten
PY  - 2017
DO  - 10.1016/j.clgc.2017.08.020
UR  - https://hdl.handle.net/10668/27740
T2  - Clinical genitourinary cancer
AB  - Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit...
LA  - en
KW  - Bone metastases
KW  - Patient selection
KW  - Targeted alpha therapy
KW  - Treatment monitoring
KW  - Treatment sequence
TI  - The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.
TY  - research article
ER  -